

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

January 02, 2026

To,
Listing Operation Department
BSE Limited
P. J. Towers,
Dalal Street, Mumbai - 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla
Complex, Bandra (East), Mumbai– 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results of the Company for Q2FY26.

The press release is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Yours Faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

Press Release: CORONA Remedies Limited Q2 and H1 FY26 Results

The Consolidated Revenue from Operations for the quarter and half year for FY26 stood at ₹ **361.13 Cr. and ₹ 707.67 Cr.** respectively. The Revenue of the above periods grew by **15.1% and 17.0%** respectively, on Y-o-Y basis.

PAT for the quarter and half year FY26 was ₹ **52.32 Cr. and ₹ 98.52 Cr.** respectively. The PAT of the above periods grew by **21.8% and 35.1%** respectively, on Y-o-Y basis.

Ahmedabad, January 02, 2026: CORONA Remedies Limited, today announced the unaudited results for the second quarter and half year ended September 30, 2025, as approved by its Board of Directors.

Q2FY26 Financial Highlights:

Particulars (₹ in Cr.)	Q2FY26	H1FY26
Revenue from Operations	361.13	707.67
Gross Profit	292.48	573.24
EBITDA	78.47	148.25
EBITDA Margin	21.7%	20.9%
Profit After Tax	52.32	98.52
Profit After Tax Margin	14.5%	13.9%

H1 FY26 Key Financial Metrics:

Particulars	H1 FY26
RoE*	31.1%
RoCE*	49.7%
OCF to EBITDA	76.5%
Net Working Capital Days	23 Days

* Annualised

Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:

“We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios.

Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.

Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”

Earnings Call:

CORONA Remedies Limited will conduct earnings call at 12:00 PM (IST) on January 05, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date & Time	Monday, January 05, 2026 12:00 PM IST 01:30 AM USA EDT 06:30 AM UK TIME 02:30 PM HK/SINGAPORE TIME
Universal Dial In	+91-22-6280 1366 / +91-22-7115 8267
International Dial In	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Diamond Pass Link	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9127751&linkSecurityString=47bf57b320

About CORONA Remedies Limited:

CORONA Remedies Limited (CORONA), founded in 2004, is an India focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/ EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 100+ team members including scientists working on new formulation development. CORONA is a proud family of 4500+ employees.

To know more about us, visit www.coronaremedies.com

For further information, please contact: Mr. Sagar Shroff, Strategic Growth Advisors Private Limited (SGA), Mobile: 98205 19303 and Email Id: sagar.shroff@sgapl.net

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
